Abstract Number: 2711 • 2017 ACR/ARHP Annual Meeting
Mucosal-Associated Invariant T Cells Are an Important Source of TNF in Rheumatoid Arthritis
Background/Purpose: CD8+ T cells have been described to comprise up to 40% of the rheumatoid arthritis (RA) synovial T cell compartment but their pathogenic function…Abstract Number: 2712 • 2017 ACR/ARHP Annual Meeting
Autoimmune Arthritis in IL-1 Receptor Antagonist-Deficient Mice Is Associated with a Pathogenic Conversion of Foxp3+ Regulatory T Cells into Th17 Cells
Background/Purpose: IL-1β blockade is a highly effective therapy for systemic juvenile idiopathic arthritis (sJIA). However, the rate of inactive disease attained in these trials is…Abstract Number: 2713 • 2017 ACR/ARHP Annual Meeting
CD318 Is a New Ligand for CD6
Background/Purpose: CD6, an important regulator of T cells, has one known ligand, CD166, but studies performed during the treatment of autoimmune conditions and in vitro…Abstract Number: 2714 • 2017 ACR/ARHP Annual Meeting
The Paracaspase MALT1 Plays a Central Role in the Pathogenesis of Rheumatoid Arthritis
Background/Purpose: One of the hallmarks of many inflammatory arthritides is their strong linkage with MHC-signalling, which is mirrored by the marked role for adaptive immunity.…Abstract Number: 2715 • 2017 ACR/ARHP Annual Meeting
NKTR-358: A Selective, First-in-Class IL-2 Pathway Agonist Which Increases Number and Suppressive Function of Regulatory T Cells for the Treatment of Immune Inflammatory Disorders
Background/Purpose: Impaired IL-2 production and regulatory T cell (Treg) dysfunctions have been implicated as an immunological mechanism in multiple autoimmune diseases. While low-dose IL-2 can…Abstract Number: 2716 • 2017 ACR/ARHP Annual Meeting
Gastrointestinal Involvement in Adult IgA Vasculitis (Henoch–Schönlein purpura): Initial Manifestations and Outcomes
Background/Purpose: Gastrointestinal (GI) involvement during adult IgA vasculitis (IgAV) occurs in roughly half the cases. In many other systemic vasculitides, GI involvement represents a poor-prognosis…Abstract Number: 2717 • 2017 ACR/ARHP Annual Meeting
Late Onset of IgA Vasculitis Is Associated with More Severe Renal Involvement
Background/Purpose: Immunoglobulin A vasculitis (IgAV), formerly called Henoch–Schönlein purpura, is a small-vessel vasculitis characterized by immune-complex deposits with predominant IgA. Although the disease is often…Abstract Number: 2718 • 2017 ACR/ARHP Annual Meeting
Is Smoking Important in Adult IgA Vasculitis?
Background/Purpose: Nicotine may predispose to kidney injury by increasing the oxidative stress, and there is known association between smoking and the progression of chronic kidney…Abstract Number: 2719 • 2017 ACR/ARHP Annual Meeting
Can Annexin A1 Expression on Neutrophils Distinguish Adult IgA Vasculitis from Other Small Vessel Vasculitides?
Background/Purpose: Immunoglobulin A vasculitis (IgAV, formerly Henoch–Schönlein purpura) is a small vessel, immune complex vasculitis characterized by dominant IgA deposits in the vascular wall. Clinical…Abstract Number: 2720 • 2017 ACR/ARHP Annual Meeting
Behcet’s Disease in Southeastern Michigan: A Single Center Comparative Study
Background/Purpose: Behçet’s disease is a heterogeneous immune-mediated disease, with clinical variability across ethnicities and geographic locations. In this study, we describe and analyze the clinical…Abstract Number: 2721 • 2017 ACR/ARHP Annual Meeting
Anti-IL6-Receptor Tocilizumab in Refractory Uveitis Associated to Extraocular Manifestations in Patients with Behçet’s Disease. Multicenter Study
Background/Purpose: To assess the efficacy of Tocilizumab (TCZ) in refractory uveitis associated to extraocular manifestations due to Behçet’s disease (BD). Methods: Multicenter study of patients…Abstract Number: 2722 • 2017 ACR/ARHP Annual Meeting
Long Term Follow-up and Optimization of Infliximab in Refractory Uveitis of Behçet’s Disease. Multicenter Study of 103 Cases
Background/Purpose: Uveitis is a severe manifestation of Behçet Disease (BD). The treatment is based on corticosteroids and conventional immunosuppressive drugs. In refractory cases, anti-TNFα had…Abstract Number: 2723 • 2017 ACR/ARHP Annual Meeting
Adalimumab Therapy Optimization in Refractory Uveitis Due to Behçet’s Disease after Achieving Remission. interventional Versus Control Group
Background/Purpose: Adalimumab (ADA) therapy has been approved by the EMA and the FDA in non-infectious and non-anterior uveitis. After loading, the maintenance dose is 40…Abstract Number: 2724 • 2017 ACR/ARHP Annual Meeting
Apremilast for Refractory Mucocutaneous Ulcers of Behçet’s Disease. National Multicenter Study of 14 Cases
Background/Purpose: Behçet´s disease (BD) is characterized by recurrent oral and/or genital ulcers accompanied by ocular, cutaneous, articular, gastrointestinal, and/or neurologic manifestations. Oral and/or genital aphthous…Abstract Number: 2725 • 2017 ACR/ARHP Annual Meeting
Understanding Vasculitis Patients’ Ability to Work with Numbers
Background/Purpose: In the case of a complex disease like vasculitis, the patient is often tasked with understanding complicated care plans and managing myriad medications. Without…
ACR Meeting Abstracts